Perioperative immunotherapy in lung cancer: Time to push the frontiers?
1Institut Curie, Paris, France; Paris Saclay, UVSQ, Versailles, France.
Abstract:
Perioperative immunotherapy is a new standard of care for the management of resectable non-small cell lung cancer (NSCLC). The TOGATHER trial assessed perioperative immunotherapy in patients with primarily nonresectable NSCLC, pushing a new concept that led to a re-evaluation of the frontiers of resectability, surgical approaches, and chemoradiotherapy.
More Related Videos
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
